Original Article Efficacy of Lacosamide as Adjunctive Therapy in Children With Refractory

Lacosamide is a US Food and Drug Administration (FDA)–approved antiepileptic drug for patients 17 years or older with partial epilepsy. There are sparse data on children. The objective of our study was to evaluate its efficacy/safety in children with refractory epilepsy. Forty children (mean age 14.3 years) were treated with lacosamide at our institution (adjunctive therapy in 36, monotherapy in 4…